AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03396757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed strategy
Description: RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice.
Study NCT02737033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Rhodiola rosea 800mg
Study NCT02737033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: innocuous pill manufactured to mimic Rhodiola
Study NCT01067443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®) and sodium stibogluconate
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
Study NCT01067443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B + miltefosine
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
Study NCT01067443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
Study NCT00458874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT results
Description: Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial.
Study NCT01906879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple, quadruple, non-bismuth quadruple therapy
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy
Study NCT01906879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple, quadruple, non-bismuth quadruple therapy
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy
Study NCT04585971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)
Study NCT02775240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose
Study NCT02775240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose
Study NCT02775240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: 200mg twice a day for 8 days
Study NCT02775240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: 30 mg oral dose
Study NCT02775240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30 mg oral dose
Study NCT04061993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength and Sensory-Motor Training
Description: Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
Study NCT04061993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
Study NCT04061993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
Study NCT00600145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
Study NCT00600145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00222105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-100 mg day 1-28
Study NCT00222105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg day 1-4 and 15-18
Study NCT04358757 — intervention group
Intervention type: PROCEDURE
Intervention: Elective cesarean delivery
Description: scheduled cesarean delivery for maternal / obstetric indications
Study NCT00526201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-weeks EnhanceFitness
Description: EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
Study NCT02498730 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Only Dependent Variables Measures
Study NCT03942874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Reward Retraining
Description: Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
Study NCT04160611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5mg
Description: The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
Study NCT03169270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
Study NCT03169270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
Study NCT00526201 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
Study NCT05241158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling with visual aid
Description: patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
Study NCT05241158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Patients counselled about the procedure, complications and the post-procedure recovery phase
Study NCT04125537 — intervention group
Intervention type: BEHAVIORAL
Intervention: IHI Breakthrough Collaborative Model
Description: Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
Study NCT04003714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
Study NCT04003714 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial Magnetic Stimulation
Description: Control group received sham r-TMS.
Study NCT01811914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative TTE
Study NCT00876642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Description: The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
Study NCT00190060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone gel (Testogel 1% )
Description: Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
Study NCT00190060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched transdermal placebo gel
Description: Matched transdermal placebo gel, 50mg/d for 6 months
Study NCT00195650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
Study NCT03251326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone capsules (4 mg)
Study NCT03251326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cigarettes (0.0 and 5.6% THC)
Study NCT03251326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol capsules (40mg)
Study NCT03251326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT00971308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 50mg, Once Daily, 3 days
Study NCT00971308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 100mg, Once Daily, 3 days
Study NCT00971308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 10mg, Once Daily, 3 days
Study NCT00971308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule. Oral, 1mg, Once Daily, 3 days
Study NCT00971308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
Study NCT05984251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.
Study NCT05984251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT02835040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New model of service delivery
Description: Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
Study NCT02835040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current practice
Description: Interventions as determined by the treating General Medical team consistent with current usual practice.
Study NCT03034239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: + insect protein
Study NCT03034239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance exercise
Study NCT03034239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Resistance exercise
Study NCT00852371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: 25 mg/kg po once on day 0
Study NCT00852371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine + sulfadoxine-pyrimethamine
Description: Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
Study NCT00852371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: 2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
Study NCT00852371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
Study NCT03450330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
Study NCT03601234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and endoscopic cooperative surgery
Description: compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
Study NCT03601234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: the traditional surgery
Study NCT02139059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: initial urinary drainage
Description: initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
Study NCT02139059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct ureteroscopy
Description: direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
Study NCT02470715 — intervention group
Intervention type: GENETIC
Intervention: Molecular profile
Description: Patients and their treating physician will obtain the patient's genetic risk assessment
Study NCT02589392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash
Study NCT02589392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® Restoraderm® body wash
Study NCT03265223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine
Description: Intraperitoneal instillation versus intraincisional infiltration
Study NCT03952390 — intervention group
Intervention type: OTHER
Intervention: control
Study NCT03952390 — intervention group
Intervention type: OTHER
Intervention: sepsis
Study NCT02160132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone(intravenously in the 1st-2nd-3rd month )
Description: Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
Study NCT02160132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone(intravenously in the 1st-3rd-5th month)
Description: Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
Study NCT04486300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic reduction and Laparotomy
Description: Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
Study NCT01814280 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication review
Description: Medication review performed by either a clinical pharmacist or a clinical pharmacologist
Study NCT04769999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Description: A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
Study NCT02384642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS
Description: COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
Study NCT02384642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS plus parenting
Description: The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
Study NCT03837522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Procurement Biopsy: Frozen section
Description: Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
Study NCT03837522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Procurement Biopsy: Permanent section
Description: Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
Study NCT01967381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine (Desoxyn®)
Description: The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
Study NCT04360447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reformer Pilates
Description: Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
Study NCT04360447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
Study NCT02898012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.